Testing Information

Testing Status of Agents at NTP

Gallium arsenide

Print this pageFriendly URL

http://ntp.niehs.nih.gov/go/TS-11192-E

CASRN: 1303-00-0

Formula: AS-GA

Synonyms/Common Names:

  • GALLIUM MONOARSENIDE

Known Uses:

SEMICONDUCTORS. MAGNETORESISTANCE DEVICES. LIGHT-EMITTING DIODES. MICROWAVE GENERATION. (TDB)

Short-Term Toxicity

  • 2-WEEK (Inhalation)  (C62033) Completed 
    • NTIS No. PB2001-102003
      Citation: Toxicology and Carcinogenesis Studies of Gallium Arsenide (CAS No. 1303-00-0) in F344/N Rats and B6C3F1 Mice (Inhalation Studies)
    • Rats: F344/N; Mice: B6C3F1
    • Dose: R & M: 0, 1, 10, 37, 75 OR 150 MG/M3 (5/S/S)
  • 13-WEEK (Inhalation)  (C62033) Completed 
    • NTIS No. PB2001-102003
      Citation: Toxicology and Carcinogenesis Studies of Gallium Arsenide (CAS No. 1303-00-0) in F344/N Rats and B6C3F1 Mice (Inhalation Studies)
    • Rats: F344/N; Mice: B6C3F1
    • Dose: R&M:0,0.1,1,10,37,75 MG/M3/20 & 10 PER GROUP RESPECTIVELY

Long-Term Carcinogenicity

  • 2-YEAR (Inhalation)  (C62033B) Report Complete 
    • TR-492 (NTIS No. PB2001-102003)  (Peer Review 05/21/1999)
      Toxicology and Carcinogenesis Studies of Gallium Arsenide (CAS No. 1303-00-0) in F344/N Rats and B6C3F1 Mice (Inhalation Studies)
    • Rats: F344/N; Mice: B6C3F1
    • Carcinogenesis Results
      • Male Rats No Evidence 
      • Female Rats Clear Evidence 
      • Male Mice No Evidence 
      • Female Mice No Evidence 
    • Dose: R: 0, 0.01, 0.1, OR 1.0 MG/M3; 50/SEX/GROUP M: 0, 0.1, 0.5, OR 1.0 MG/M3; 50/SEX/GROUP

Special Studies

  • Absorption Disposition Metabolism Elimination (Gavage; Intratracheal)  (S0144) Completed 
    • Citation: CARTER, D.E. & BELLAMY, W.T.: TOXICOLOGY OF THE GROUP III-V INTERMETALLIC SEMICONDUCTOR, GALLIUM ARSENIDE,"BIOLOGICAL MONITORING OF TOXIC METALS", T.W. CLARKSON, L. FRIEBERG, G.F. NORDBERG & P.S. SAGER, (EDS.), PLENUM PUBLISHING CORP., P. 455-468, 1988.
    • M Rats; M Rats
    • Dose: PO:10,100,1000 INTRATRACHEAL:100 MG/KG
  • Absorption Disposition Metabolism Elimination (Intratracheal)  (S0444) Completed 
    • Citation: WEBB, D.R., ET.AL., PULMONARY CLEARANCE & TOXICITY OF RESPIRABLE GAAS PARTICULATES INTRATRACHEALLY INSTILLED INTO RATS, AM IND HYG ASSOC 48(7):660-667, 1987***** WEBB, ET.AL., COMPARATIVE PULMONARY TOXICITY OF GAAS, GA(III) OXIDE OR AS(III) OXIDE INTRATRACHEALLY INSTILLED IN RATS, TOXICOL & APPL PHARM 82:405-416,1986.
    • M Rats: F344/N
    • Dose: 100 mg/kg
  • Absorption Disposition Metabolism Elimination (Gavage; Intratracheal)  (S0445) Completed 
    • Citation: WEBB, D.R., ET.AL., IN VITRO SOLUBILITY & INVIVO TOXICITY OF GALLIUM ARSENIDE, TOXICOL & APPL PHARM 76:96-104, 1984.
    • M Rats: F344/N; M Rats: F344/N
    • Dose: 10, 100, or 1000 mg/kg for gavage. 10, 30, or 100 mg/kg for Intratracheal
  • Absorption Disposition Metabolism Elimination (Intratracheal)  (S0470) Completed 
    • Citation: ROSNER, M.H. & CARTER, D.E., METABOLISM & EXCRETION OF GAAS & AS OXIDES BY HAMSTERS FOLLOWING INTRTRACHEAL INSTILLATION, FUND & APPL TOXICOL 9:730-737,1987.
    • M Hamsters: Syrian Golden
  • Absorption Disposition Metabolism Elimination (Gavage; Intratracheal)  (S0766) Completed 
    • Citation: FINAL REPORT OF CONTRACT # N01-ES-8-2130. BY SIPED, ILGL, & CARTER, DE.
    • Rats; Rats
    • Dose: gavage, 10, 100 or 1000 mg/kg. intratracheal 10, 30, 0r 100 mg/kg
  • Absorption Disposition Metabolism Elimination (Intratracheal)  (S0767) Completed 
    • Citation: WEBB, D.R., WILSON, S.E., & CARTER, D.E. PULMONARY CLEARANCE AND TOXICITY OF RESPIRABLE GALLIUM ARSENIDE PARTICULATES INTRATRACHEALLY INSTILLED INTO RATS. AM. IND. HYG. ASOC J 48 (7): 660-667 (1987)
    • M Rats: F344/N
  • Toxicokinetic Study (Inhalation)  (S0564) Completed 
    • M/F Rats: F344/N; M/F Mice: B6C3F1
    • Dose: RAT: 0, 0.01, 0.1, & 1.0 MG/M3; MICE: 0, 0.1, 0.5, & 1.0 MG/M3

Genetic Toxicology

  • Micronucleus  (A56833) Completed 
    • Citation: Witt, K.L., Knapton, A., Wehr, C.M., Hook, G.J., Mirsalis, J., Shelby, M.D., and MacGregor, J.T. Micronucleated Erythrocyte Frequency in Peripheral Blood of B6C3F1 Mice from Short-Term, Prechronic, and Chronic Studies of the NTP Carcinogenesis Bioassay Program. Environ. Molec. Mutagen. Vol. 36 (2000) 163-194
    • Mice: B6C3F1
    • Male Negative 
    • Female Negative 
  • Salmonella  (006180) Completed 
    • Citation: Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., and Mortelman, K. Salmonella Mutagenicity Tests V. Results from the Testing of 311 Chemicals Environ. Molec. Mutagen. Vol. 19 (Suppl 21) (1992) 2-141
    •  Negative 

Organ Systems Toxicity

  • Immunotoxicity (Intratracheal)  (IMM90013) Completed 
    • NTIS No. PB92-140383
      Citation: Summary Reports on Immunotoxicology Vol. 1, No. 1-15
    • Citation: SUMMARY (1-15)
    • F Mice: B6C3F1
    • Mice Female Positive 
    • Dose: 0, 50, 100, 200 MG/KG
  • GD 4-19 Conventional Teratology (Inhalation)  (TER89143) Completed 
    • Citation: DE91005300/XAB
    • Rats: Sprague Dawley
    • Rats Maternal Positive 
    • Rats Fetal Positive 
    • Dose: 0, 10, 37, 75 MG/CUBIC METER
  • GD 4-17 Conventional Teratology (Inhalation)  (TER90043) Completed 
    • Citation: DE91005300/XAB
    • F Mice: Swiss
    • Mice Maternal Positive 
    • Mice Fetal Positive 
    • Dose: 10, 37, 75 MG/CUBIC METER

Back to top

Web page last updated on January 22, 2009